Abstract
Heart transplant recipients are at a high risk for the development of post-transplant lymphoproliferative disorders (PTLD). We explored the relationship between the incidence of PTLD and the immunosuppressive therapy in 150 consecutive patients who received a cardiac transplant at our centre. None of our patients treated with cyclosporin A and prednisone only (n = 41) developed PTLD. In contrast, 6 of 101 patients who were previously treated with anti-T-cell preparations suffered from PTLD. No relationship was found between the type of anti-T-cell therapy and the incidence of PTLD. We conclude that the high incidence of PTLD in heart transplant recipients is related to the total immunosuppressive load and not related to a single agent like OKT3.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Transplant international : official journal of the European Society for Organ Transplantation
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
